Protective multi-epitope candidate vaccine for urinary tract infection

Oloomi, Mana; Javadi, Maryam; Karam, Mohammad Reza Asadi; Khezerloo, Jamil Kheirvari; Haghri, Zohreh; Bouzari, Saeid

doi:10.1016/j.btre.2020.e00564

“…Epitope-based vaccines derived through the immunoinformatics approach have received wide recognition in the design of novel vaccines against different pathogens [ 19 , 20 , 21 ]. The potential advantages of this vaccine vis-à-vis cost-effectiveness and the ability to induce both humoral and cellular immunity make it a suitable alternative vaccine for the control of CAV infection.…”

Section: Introductionmentioning

confidence: 99%

Design of a Multiepitope Vaccine against Chicken Anemia Virus Disease

Fatoba

¹

,

Adeleke

²

,

Maharaj

³

et al. 2022

Viruses

View full text Add to dashboard Cite

Chicken anemia virus (CAV) causes severe clinical and sub-clinical infection in poultry globally and thus leads to economic losses. The drawbacks of the commercially available vaccines against CAV disease signal the need for a novel, safe, and effective vaccine design. In this study, a multiepitope vaccine (MEV) consisting of T-cell and B-cell epitopes from CAV viral proteins (VP1 and VP2) was computationally constructed with the help of linkers and adjuvant. The 3D model of the MEV construct was refined and validated by different online bioinformatics tools. Molecular docking showed stable interaction of the MEV construct with TLR3, and this was confirmed by Molecular Dynamics Simulation. Codon optimization and in silico cloning of the vaccine in pET-28a (+) vector also showed its potential expression in the E. coli K12 system. The immune simulation also indicated the ability of this vaccine to induce an effective immune response against this virus. Although the vaccine in this study was computationally constructed and still requires further in vivo study to confirm its effectiveness, this study marks a very important step towards designing a potential vaccine against CAV disease.

show abstract

“…Various advantages of this approach include increased safety, the opportunity to rationally engineer the epitopes for increased potency and breadth, and the ability to focus immune responses on conserved epitopes (45). Nowadays the multi-epitope vaccine designing is a prominent eld that luckily has not only demonstrated a promising in vivo e cacy with protective immunity (46,47,48,49,50,51,52,53) but also achieved phase-I clinical trials (54,55,56,57,58). Recently in the same approach, the immunoinformatics designed vaccine has been used for designing multi-epitope vaccines against Nipah virus (59), Malaria (60), Hendra virus (61), Leishmania (62), and also Zika virus (63).…”

Section: Discussionmentioning

confidence: 99%

CD171 multi‑epitope peptide design based on immunoinformatics approach as a cancer vaccine candidate for glioblastoma

Moghri

¹

,

Chalbatani

²

,

Ranjbar

³

et al. 2021

Preprint

1

0

View full text Add to dashboard Cite

Glioblastoma (GB) is a common primary malignancy of the central nervous system, and one of the highly lethal brain tumors. GB cells can promote therapeutic resistance and tumor angiogenesis. The CD171 is an adhesion molecule in neuronal cells that is expressed in glioma cells as a regulator of brain development during the embryonic period. CD171 is one of the immunoglobulin-like CAMs (cell adhesion molecules) families that can be associated with prognosis in a variety of human tumors. The multi-epitope peptide vaccines are based on synthetic peptides with a combination of both B-cell epitopes and T-cell epitopes, which can induce specific humoral or cellular immune responses. Moreover Cholera toxin subunit B (CTB), a novel TLR agonist was utilized in the final construct to polarize CD4+ T cells toward T-helper 1 to induce strong cytotoxic T lymphocytes (CTL) responses. In the present study, several immune-informatics tools were used for analyzing the CD171 sequence and studying the important characteristics of a designed vaccine. The results included the molecular docking, prediction and validation of the secondary and tertiary structure, physicochemical properties, solubility, conservancy, toxicity as well as antigenicity and allergenicity of the promising candidate for a vaccine against CD171. The immuno-informatic analyze suggested 12 predicted multi-epitope peptides, whose construction consists of 582 residues long. Therewith, cloning adaptation of designed vaccine was performed and eventually sequence was inserted into pET30a (+) vector for the application of the anti-glioblastoma vaccine development.

show abstract

“…Various advantages of this approach include increased safety, the opportunity to rationally engineer the epitopes for increased potency and breadth, and the ability to focus immune responses on conserved epitopes (45). Nowadays the multi-epitope vaccine designing is a prominent eld that luckily has not only demonstrated a promising in vivo e cacy with protective immunity (46,47,48,49,50,51,52,53) but also achieved phase-I clinical trials (54,55,56,57,58). Recently in the same approach, the immunoinformatics designed vaccine has been used for designing multi-epitope vaccines against Nipah virus (59), Malaria (60), Hendra virus (61), Leishmania (62), and also SARS-CoV-2 (63).…”

Section: Discussionmentioning

confidence: 99%

CD171 multi‑epitope peptide design based on immunoinformatics approach as a cancer vaccine candidate for glioblastoma

Moghri

¹

,

Chalbatani

²

,

Ranjbar

³

et al. 2021

Preprint

0

View full text Add to dashboard Cite

Glioblastoma (GB) is a common primary malignancy of the central nervous system, and one of the highly lethal brain tumors. GB cells can promote therapeutic resistance and tumor angiogenesis. The CD171 is an adhesion molecule in neuronal cells that is expressed in glioma cells as a regulator of brain development during the embryonic period. CD171 is one of the immunoglobulin-like CAMs (cell adhesion molecules) families that can be associated with prognosis in a variety of human tumors. The multi-epitope peptide vaccines are based on synthetic peptides with a combination of both B-cell epitopes and T-cell epitopes, which can induce specific humoral or cellular immune responses. Moreover Cholera toxin subunit B (CTB), a novel TLR agonist was utilized in the final construct to polarize CD4+ T cells toward T-helper 1 to induce strong cytotoxic T lymphocytes (CTL) responses. In the present study, several immune-informatics tools were used for analyzing the CD171 sequence and studying the important characteristics of a designed vaccine. The results included the molecular docking, prediction and validation of the secondary and tertiary structure, physicochemical properties, solubility, conservancy, toxicity as well as antigenicity and allergenicity of the promising candidate for a vaccine against CD171. The immuno-informatic analyze suggested 12 predicted multi-epitope peptides, whose construction consists of 582 residues long. Therewith, cloning adaptation of designed vaccine was performed and eventually sequence was inserted into pET30a (+) vector for the application of the anti-glioblastoma vaccine development.

show abstract

Protective multi-epitope candidate vaccine for urinary tract infection

Cited by 7 publications

References 30 publications

Design of a Multiepitope Vaccine against Chicken Anemia Virus Disease

Design of a Multiepitope Vaccine against Chicken Anemia Virus Disease

CD171 multi‑epitope peptide design based on immunoinformatics approach as a cancer vaccine candidate for glioblastoma

CD171 multi‑epitope peptide design based on immunoinformatics approach as a cancer vaccine candidate for glioblastoma

Contact Info

Product

Resources

About